Compare Spotify Technology (SPOT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spotify Technology vs TransMedics Group Inc — how do they compare? Spotify Technology trades at $489.6 (market cap $103.00B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Spotify Technology is far larger — about 33.2× TransMedics Group Inc's market cap. Which is the better fit depends on your goals.
| SPOT | TMDX | |
|---|---|---|
Market Cap | $103.00B | $3.10B |
Sector | Media | Technology |
52-Week High | $738.53 | $150.42 |
52-Week Low | $412.75 | $61.99 |
Enterprise Value | $92.70B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Spotify (SPOT) trades at $486.44, down 4.96% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong revenue growth to $17.19B in 2025 and net income of $2.21B, with a record 300 million Premium subscribers in Q2 2026. Recent news highlights Spotify's initiative to label AI-generated artists for transparency, reflecting proactive content management.
The outlook remains positive with a consensus price target of $598.20, implying significant upside. Key risks include rising marketing and AI costs impacting margins, as seen in the Q2 2026 earnings miss. Investor sentiment is buoyed by subscriber growth and monetization efforts, but execution on cost control will be critical for sustained gains.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
